Eli Lilly antibody therapy, donanemab,

Pharmaceutical company Eli Lilly on Monday announced positive findings for its drug in the fight against Alzheimer’s disease.

The investigational antibody therapy, donanemab, slowed cognitive decline by a statistically significant 32% compared to a placebo, Lilly said. The drug met a main objective to slow decline in about 18 months.

Donanemab works by targeting a so-called N3pG beta amyloid to quickly clear amyloid plaques in the brain, which otherwise disrupt cell function, according to the National Institutes of Health.